BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) — Healthcare · Share Price, Chart & Market Data
About: BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $8.78 (-2.12%)
BBOTBridgeBio Oncology Therapeutics, Inc.
Loading watchlist status…
Trade BBOT now
BridgeBio Oncology Therapeutics, Inc. share price
BBOT price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 7:27 am GMT+0
BBOT price performance
-5.184%
5D
0.688%
1M
-28.56%
YTD
-12.2%
1Y
BBOT price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 7:27 am GMT+0
BBOT details
BBOT Market Signals